INVESTIGADORES
GARCÍA MARTÍ SebastiÁn
artículos
Título:
NEW TREATMENTS FOR MALIGNANT ADVANCED MELANOMA FOR ADULT PATIENTS IN TUNISIA: INEAS HTA REPORT AND IMPACT ON REIMBURSEMENT DECISION
Autor/es:
JAMELEDDINE, M; GRATI, H.; JEBALI, M. C.; HARZALLAH, N.; GARCÍA-MARTÍ, SEBASTIAN; SOTO, NATALIE C; PICHÓN-RIVIERE, ANDRÉS; HAMOUDA, C.
Revista:
ELSEVIER SCIENCE B. V.
Editorial:
Elsevier
Referencias:
Año: 2020
Resumen:
ObjectivesMalignant melanoma is the most serious form of skin cancer. The prognosis for patients at metastatic or unresectable stage remains poor. Dacarbazine is the standard of care in Tunisia despite low response rates. INEAS, the Tunisian HTA body has just finalized, at the national payers request, an HTA report aiming to inform reimbursement decision for two new drugs as monotherapies for advanced melanoma in adults ; nivolumab and vemurafenib (only for BRAF V600 mutation-positive patients).
